The field of RNA therapeutics has expanded incredibly in the past 30 years, and mRNA-based COVID-19 vaccines were just the start.
Clinical trials of an mRNA vaccine have begun, and researchers expect broadly positive outcomes in the fight against the widespread illness.
When Monash University announced world-first COVID-19 research in July, the crucial behind-the-scenes work of a group of PhD students went largely unnoticed.
The delivery of a COVID-19 vaccine still needs to overcome some ethical hurdles.
How likely is it that we'll have a relatively quick fix for COVID-19, and what are the hurdles?
Critically ill patients from intensive care units are part of a global trial testing a suite of flu and pneumonia drugs in a bid to combat COVID-19.
Deliberately infecting people with a disease-causing agent as part of medical research can be ethically acceptable, and even necessary.
Dummy text
